Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jan 19;22(1):82.
doi: 10.1186/s12885-021-09124-5.

Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study

Affiliations
Multicenter Study

Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study

Geoffrey C Buckle et al. BMC Cancer. .

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radiation therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined.

Methods: This prospective, observational, multi-center, open cohort study aims to describe the therapeutic landscape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Tenwek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach.

Discussion: This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research.

Trial registration: This study was retrospectively registered with the ClinicalTrials.gov database on December 15, 2021, NCT05177393 .

Keywords: Africa; Comparative effectiveness; Eastern Africa; Esophageal cancer; Esophageal squamous cell carcinoma; Quality of life; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

Figures

Fig. 1
Fig. 1
Map of African Esophageal Cancer Consortium (AfrECC) study sites. “Map of African Esophageal Cancer Consortium (AfrECC) sites” published by Van Loon et al. The African Esophageal Cancer Consortium: A Call to Action. J Glob Oncol. 2018 Sep;4:1-9. Licensed under Creative Commons Attribution 4.0. Participant sites modified from original. License: https://creativecommons.org/licenses/by/4.0/

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:caac.21660. 10.3322/caac.21660. - PubMed
    1. Malekzadeh R, Abnet CC, Dawsey SM. Oesophageal cancer: a tale of two malignancies. In: Wild CP, Weiderpass E, Stewart BW, editors. World cancer report: cancer research for cancer prevention. International Agency for Research on Cancer; 2020.
    1. Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015;39(2):143–149. doi: 10.1016/j.canep.2015.01.001. - DOI - PMC - PubMed
    1. Abnet CC, Arnold M, Wei W-Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373. doi: 10.1053/j.gastro.2017.08.023. - DOI - PMC - PubMed
    1. Buckle GC, Mahapatra R, Mwachiro M, Akoko L, Mmbaga EJ, White RE, et al. Optimal management of esophageal cancer in Africa: a systemic review of treatment strategies. Int J Cancer. 2020. 10.1002/IJC.33299. - PubMed

Publication types

Associated data